Previous close | 244.96 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 4,996 |
Market cap | 4.911B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 0.83 |
EPS (TTM) | 6.52 |
Earnings date | 30 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The stock market's very rough April saw some of the biggest gainers of the first three months take some of the biggest dings to their market caps. And at the same time, some of the sectors that struggled in Q1 saw a similar reversal of fortune in April.
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Eli Lilly reported strong sales of weight-loss drug Zepbound in the first quarter. Is Eli Lilly stock a buy?